Second-look TURBT: evaluation of anatomopatological and oncologic results in a single center

Main Article Content

Matteo Maltagliati
Virginia Varca
Riccardo Milandri
Salvatore Micali
Tommaso Bocchialini
Bernardo Maria Cesare Rocco
Andrea Gregori

Keywords

second-look TURBT, Re-TURBT, bladder cancer, NMIBC, cistectomy

Abstract

Introduction: T1 bladder cancer is associated with a high risk of recurrence and progression; concomitant carcinoma in situ and/or multifocality are negative prognostic factors. Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, and after resection of High-grade (HG) Ta tumour in 41,4%. It has been demonstrated that a second TURB can increase recurrence-free survival and it can make a restaging of the cancer. Patients and methods: From January 2011 to December 2016, 87 patients with superficial bladder tumor (Ta-T1), undergoing TURB and routine repeat TURB (Re-TURB) 4-6 weeks after the initial resection, were included in the study. Re-TURB was applied to the scar of the first resection and other suspicious lesions in the bladder. After the second-look, we studied the follow-up of each patient. Results: Specimens obtained during the second TURBT showed no tumor in 47 (54,02%) patients; 40 (45,98%) patients had residual cancer: 34 of them had cancer of the same stage, 6 patients of pT1 had a lower stage, and 3 had a higher stage. 5 patient underwent radical cistectomy immediatly after re-TURBT. During the first year of follow up, 15 patients had a recurrent bladder cancer; 2 of them underwent radical cistectomy. Conclusions: T1 bladder cancer is an high risk tumor, so that second-look TURBT is a valuable procedure for accurate staging of nonmuscle-invasive bladder cancer and it can guarantee a better eradication of the neoplasm.

a

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 109 | PDF Downloads 49

References

[1] Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007 Oct;70(4):758-62.
[2] Vasdev N, Dominguez-Escrig J, Paez E, et al. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience. 2012.
[3] Lazica DA, Roth S, Brandt AS, et al. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 2014.
[4] M. Babjuk (Chair), A. Böhle, M. Burger, et al. Guidelines on non-muscle-invasive bladder Cancer (Ta, T1 and CIS), European Association of Urology 2015.
[5] Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006 Mar).
[6] Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology (2005).
[7] Aydin M1, Tandogdu Z, Kurtulus FO, Avci E, Fazlioglu A, Cek M., A prospective evaluation of second transurethral resection in non-muscle invasive bladder tumors, J BUON. 2010 Jul-Sep;15(3):514-7.

Most read articles by the same author(s)